Correlation of peroxisome proliferator-activated receptor-γ (PPAR-γ) and retinoid x receptor-α (RXR-α) expression with clinical risk factors in patients with advanced carotid atherosclerosis

Medical Science Monitor

Volumn 17, Issue 7, 2011, Pages

  Giaginis, Constantinos ^a,b   Klonaris, Christos ^b   Katsargyris, Athanasios ^b   Kouraklis, Gregorios ^b   Spiliopoulou, Chara ^a   Theocharis, Stamatios ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Carotid atherosclerosis; Immunohistochemistry; Macrophages; PPAR ; RXR ; Smooth muscle cells

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOID X RECEPTOR ALPHA;

AGE; AGED; ARTICLE; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DOWN REGULATION; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PROTEIN EXPRESSION; RISK FACTOR; SEX DIFFERENCE; SMOOTH MUSCLE FIBER; STROKE; TRANSIENT ISCHEMIC ATTACK; TRANSITIONAL BLINDNESS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 79959962986     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.881849     Document Type: Article

References (15)

1. Hansson GK: Infammatory mechanisms in atherosclerosis. J Thromb Haemost, 2006; 1: 328-331
2. Bonora E: The metabolic syndrome and cardiovascular disease. Ann Med, 2006; 38: 64-80
3. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP: Established and emerging vascular risk factors and the development of aortic stenosis: an opportunity for prevention? Expert Opin Ther Targets, 2008; 12: 809-820
4. Niessner A, Goronzy JJ, Weyand CM: Immune-mediated mechanisms in atherosclerosis: prevention and treatment of clinical manifestations. Curr Pharm Des, 2007; 13: 3701-3710
5. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation, 2002; 105: 1135-1143
6. Spagnoli LG, Bonnano E, Sangiorgi G, Mauriello A: Role of inflammation in atherosclerosis. J Nucl Med, 2007; 48: 1800-1815
7. Mallika V, Goswami B, Rajappa M: Atherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspective. Angiology, 2007; 58: 513-522
8. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev, 1999; 20: 649-688
9. Nolte RT, Wisely GB, Westin S et al: Ligand binding and co-activator assembly of the peroxisome proliferators activated receptor-γ. Nature, 1998; 395: 137-143
10. Hamza MS, Pott S, Vega VB, et al: De-novo identification of PPARgamma/ RXR binding sites and direct targets during adipogenesis. PLoS Onem 2009; 4: e4907
11. Germain P, Chambon P, Eichele G et al: International Union of Pharmacology. LXIII Retinoid X Receptors. Pharmacol Rev, 2006; 58: 760-772
12. Szanto A, Narkar V, Shen Q et al: Retinoid X receptors: X-ploring their (patho)physiological functions. Cell Death Differ, 2004; 2: S126-S143
13. Zoete V, Grosdidier A, Michielin O: Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta, 2007; 1771: 915-925
14. Feige JN, Gelman L, Michalik L et al: From: molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res, 2006; 45: 120-159
15. Sugden MC, Zariwala MG, Holness MJ: PPARs and the orchestration of metabolic fuel selection. Pharmacol Res, 2009; 60: 141-150